Press Releases

Mapi Pharma Closes $10 Million Investment Led by Shavit Capital

Mapi Pharma Closes $10 Million Investment Led by Shavit Capital

Ness Ziona, Israel, May 27, 2015 — Mapi Pharma Ltd. announced today that Shavit Capital has led an investment round of $10 million in the company in a Series A financing round that included participation by the company’s chairman and CEO Mr. Ehud Marom.   The…

Continue reading →

First Patient Treated in Mapi Pharma’s Phase IIa Clinical Trial  of GA Depot for Relapsing Remitting Multiple Sclerosis (RRMS)

First Patient Treated in Mapi Pharma’s Phase IIa Clinical Trial of GA Depot for Relapsing Remitting Multiple Sclerosis (RRMS)

Ness Ziona, Israel, December 17, 2014 — Mapi Pharma Ltd. announced today that the first patient was treated in the company’s Phase IIa study of GA Depot, in development as a treatment for relapsing remitting multiple sclerosis (RRMS).  Glatiramer Acetate is the active ingredient in…

Continue reading →

Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis

Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis

GA Depot Patent Release – May 27 2014 Ness Ziona, Israel, May 27, 2014 —- Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of high-barrier to entry and high value-added generic drugs, announced today that its US patent for the company’s Glatiramer Acetate Depot…

Continue reading →

Mapi Pharma Granted United States Patent for the Preparation of Fingolimod for Multiple Sclerosis

Mapi Pharma Granted United States Patent for the Preparation of Fingolimod for Multiple Sclerosis

Tuesday, February 18, 2014 Mapi Pharma Granted United States Patent Covering the Process for the Preparation of Fingolimod for Multiple Sclerosis The patent covers intermediate compounds and processes for the preparation of Fingolimo Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of high-barrier to…

Continue reading →

Mapi Pharma Granted United States Patent for Pain Relief Medication “Tapentadol”

Mapi Pharma Granted United States Patent for Pain Relief Medication “Tapentadol”

Tuesday, June 18, 2013 Mapi Pharma Granted United States Patent for Pain Relief Medication “Tapentadol” The patent covers the process and preparation of Tapentadol for the treatment of moderate to severe-acute pain Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic…

Continue reading →

Mapi Pharma Granted United States Patent covering Glatiramer Depot for Multiple Sclerosis

Mapi Pharma Granted United States Patent covering Glatiramer Depot for Multiple Sclerosis

Morbi posuere, augue adipiscing cursus ullamcorper, turpis urna volutpat urna, a pulvinar massa sem sit amet diam. Etiam at ante erat, id aliquam nisi. Integer vitae nibh tellus. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Morbi rhoncus lorem ac risus iaculis adipiscing. Sed sollicitudin euismod velit. Suspendisse pretium tempus sollicitudin. Proin augue felis, posuere id elementum et, accumsan at sem. Vivamus non facilisis quam. Nunc pellentesque pulvinar vestibulum. Aliquam convallis erat a enim dictum et vestibulum nibh rutrum. In mi nisi, hendrerit in pellentesque pellentesque, blandit a ipsum. Nam aliquet commodo nulla nec lobortis. Curabitur aliquet, urna a tempus iaculis, lorem augue tristique augue, sed aliquet sapien ligula nec lorem.

Continue reading →